Comparative Efficacy, Safety, PK, and Immunogenicity Study

Osteoporosis, Postmenopausal Clinical Trial

Official title:

A Randomized, Double-blind, Parallel-group, Active-controlled Comparative Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Immunogenicity of LY06006 Compared With EU-Prolia in Postmenopausal Women With Osteoporosis

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT05853354
• Other study ID #: LY06006/MRCT-301
• Secondary ID: IND 1385912022-0
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: April 5, 2023
• Est. completion date: December 30, 2025

Study information

• Verified date: April 2024
• Source: Luye Pharma Group Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

this comparative clinical study is designed to demonstrate that LY06006 and EU-Prolia have no clinically meaningful differences in clinical efficacy, pharmacodynamic (PD), safety, PK, and immunogenicity in postmenopausal women with osteoporosis.

Description:

This is a randomized, double-blind, parallel-group, active-controlled, comparative study (Main Period) with a Transition Period to compare the efficacy, PD, safety, PK, and immunogenicity of LY06006 and EU-Prolia among female participants with postmenopausal osteoporosis. Participants will go through a Screening Period within 35 days prior to first dosing. After signing the informed consent form (ICF), participants will be screened for age, menopausal status, and vitamin D levels, in addition to other inclusion/exclusion criteria. Participants will also undergo a screening DXA examination. Eligibility is based on the absolute value consistent with a T-score ≤ -2.5 and ≥ -4.0 at the lumbar spine. Main Period Upon completing all screening assessments and meeting all eligibility criteria, participants will enter the Main Period of the study. The Main Period will last 12 months where participants will be randomized in a 1:1 ratio to receive either a dose (60 mg/1 mL) of LY06006 or EU-Prolia subcutaneously at the Baseline Visit (Day 1) and Month 6. All participants will receive daily supplements of elemental calcium (at least 1000 mg) and vitamin D (at least 400 IU). Study visits will occur at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12. Follow-up BMD assessment will be done at Months 6 and 12. Blood sampling for PD, safety, PK, and immunogenicity will be done at the Baseline Visit (Day 1), and at Months 0.5, 1, 2, 3, 6, 9, and 12. Transition Period The Transition Period will be conducted in all participants who completed the Main Period of the study. At Month 12, participants who received EU-Prolia in the Main Period will be re-randomized in a 1:1 ratio to either be transitioned to receive a dose of LY06006 or continue on EU-Prolia subcutaneously. Participants who received LY06006 in the Main Period will be re-randomized to continue to receive LY06006 in the Transition Period. All participant assignment during the Transition Period will be performed via the interactive response technology (IRT) system to maintain the blind of treatment assignment. Blood sampling for PD, safety, PK, and immunogenicity will be done at Months 15 (PK and immunogenicity only) and 18. End of study (EoS) assessments will be performed at Month 18 or at the time of early discontinuation or withdrawal of the participant. The duration of the clinical phase for participants from the Screening Period until the EoS Visit is approximately 19 months (up to 5 weeks of Screening Period, 12 months of Main Period, and 6 months of Transition Period).

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 392
• Est. completion date: December 30, 2025
• Est. primary completion date: July 30, 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 60 Years to 90 Years

Eligibility

Inclusion Criteria:

Age

1. Participant is = 60 to = 90 years of age inclusive, at the time of signing the informed consent. Type of Participant and Disease Characteristics

2. Participant is an ambulatory postmenopausal woman (defined as lack of menstrual period for at least 12 months prior to Screening Visit, for which there is no other obvious pathological or physiological cause).

• Serum FSH test can be done at the Screening Visit in case of uncertainty.
• Female participants who underwent bilateral oophorectomy (with or without hysterectomy) at least 6 weeks prior to the Screening Period are eligible to participate.

3. Participant is diagnosed with osteoporosis, with absolute BMD consistent with a T-score of = -2.5 and = -4.0 at the lumbar spine (L1-L4 region) as measured by DXA at the Screening Visit.

4. Participant has at least two lumbar vertebrae in L1-L4 region and one hip evaluable by DXA for BMD measurement at the Screening Visit. Weight 5. Participant has body weight = 50 kg and = 90 kg at Screening. Informed Consent 6. Participant is able to read and understand, and willing to provide signed informed consent as described in Appendix 1, Section 10.1.3 which includes compliance with the requirements and restrictions listed in the ICF and in this protocol. - Exclusion Criteria: Medical Conditions

1. Participant has a history and/or presence of any severe or more than two moderate vertebral fractures as determined by central reading of lateral spine X-ray at Screening Visit.

2. Participant has a history and/or presence of hip fracture.

3. Participant has a history and/or presence of atypical femur fracture.

4. Participant presents with any active healing fracture, per assessment of the Investigator.

5. Participant has a history of bilateral hip replacement (unilateral is allowed if the other hip is evaluable by DXA).

6. Participant has history and/or presence of osteonecrosis of the external auditory canal.

7. Evidence of any of the following conditions which may affect BMD or interfere with the

interpretation of the findings:

1. Participant has a history of bone disease e.g., osteomalacia, osteopetrosis, Paget's disease, or osteogenesis imperfecta.

2. Participant has a history of metabolic or other endocrinologic diseases such as Cushing's disease, hyperprolactinemia, hypopituitarism, acromegaly, malabsorption syndrome (or any gastrointestinal disorders associated with malabsorption, e.g., Crohn's disease and chronic pancreatitis).

3. Participant has a history of chronic inflammatory diseases, obvious sclerosis, osteophytosis, severe scoliosis, or other degenerative changes due to other co-morbidities.

4. Participant has a history or current hyperparathyroidism or hypoparathyroidism. Note: Mild non-clinically significant secondary hyperparathyroidism may be acceptable upon discussion with the Medical Monitor.

5. Participant has current uncontrolled hyperthyroidism or hypothyroidism. Note:

Participants with hypothyroidism who are on stable thyroid hormone replacement

therapy may be allowed per the following criteria:

• If TSH level is within normal range, the participant is eligible.
• If TSH level is elevated (> 5.5 µIU/mL and = 10.0 µIU/mL) and serum free T4 is within normal range, the participant is eligible. If TSH is below the lower level of normal, the participant should be excluded.

6. Participant has other disease conditions where there is bone/joint involvement (e.g., rheumatoid arthritis, ankylosing spondylitis, gout, multiple myeloma, achondroplasia, bone metastases, renal osteodystrophy, osteomyelitis).

8. Participant has hypocalcemia (defined as albumin adjusted serum calcium level < 2.0 mmol/L [8.0 mg/dL] Grade 2 per Common Terminology Criteria for Adverse Events version 5.0) or hypercalcemia (defined as albumin adjusted serum calcium levels > 2.62 mmol/L [10.50 mg/dL]).

9. Participant has vitamin D deficiency (defined as 25-hydroxy vitamin D level < 20 ng/mL [< 50 nmol/L]). Note: Oral replenishment of vitamin D is permitted at the discretion of the Investigator and in accordance with local standard of care during the Screening Period. Participants can be enrolled if a repeat test (post supplementation) prior to enrollment shows corrected 25-hydroxy vitamin D level = 20 ng/mL (= 50 nmol/L).

10. Participant has any malignancy (except fully resected cutaneous basal cell or squamous cell carcinoma, cervical or breast ductal carcinoma in situ) within the last 5 years.

11. Participant has known history of liver cirrhosis.

12. Participant has known history of hepatitis B, hepatitis C, or HIV infection, or an active infection including, but not limited to SARS-CoV-2, tests positive for hepatitis B (positive HBsAg, positive anti-HBc with negative anti-HBs), hepatitis C (hepatitis C antibody), or HIV antibody during the Screening Period.

13. Participant has oral or dental conditions:

1. Prior history or current evidence of osteomyelitis or osteonecrosis of the jaw.

2. Active dental or jaw condition which requires oral surgery.

3. Invasive dental procedure planned during the study or within the past 6 months (e.g., tooth extraction, dental implants, oral surgery).

4. Non-healed dental or oral surgery.

5. Active periodontal disease.

6. Poor oral hygiene.

14. Participant has a history of major surgery within 8 weeks prior to the Screening Period or planned, anticipated major surgery during the study.

15. Participant has a history and/or presence of significant cardiac disease or ECG abnormalities indicating significant risk for participating in the study as judged by the Investigator. Prior/Concomitant Therapy

16. Participant shows contraindications to denosumab therapy (e.g., hypocalcemia), or calcium or vitamin D supplementation before starting study intervention administration.

17. Participant requires ongoing use of any osteoporosis treatment (other than calcium and vitamin D supplements).

18. Use of any of the below medications that can affect BMD:

l. Denosumab used at any time prior to Screening Visit.

1. Oral bisphosphonates at any dose for osteoporosis treatment:

• Used for > 3 years cumulatively at Screening Visit.
• At any dose used within 1 year prior to Screening Visit (if = 3 years of use cumulatively).

2. Intravenous bisphosphonate at any dose within 5 years prior to Screening Visit.

3. PTH or PTH analogues at any dose within 2 years prior to Screening Visit.

4. Systemic HRT (oral or transdermal estrogen), SERMs, tibolone, aromatase inhibitors, or androgens at any dose within 1 year prior to Screening Visit. Note: Exceptionally, non-systemic vaginal estrogen treatment is permitted.

5. Calcitonin, or its derivatives, and calcimimetics (such as cinacalcet or etelcalcetide) at any dose within 12 months prior to Screening Visit.

6. Calcitriol, alfacalcidol, or eldecalcitol within 3 months of the Screening Visit.

7. Fluoride or strontium at any dose at any time prior to Screening Visit.

8. Romosozumab or cathepsin K inhibitors received at any time prior to Screening Visit.

9. Systemic glucocorticoids (= 5 mg prednisone or equivalent per day for more than 10 days or cumulative = 50 mg) within 3 months prior to Screening Visit.

10. Other bone active drugs including anticonvulsants (except benzodiazepines, gabapentin, and pregabalin), heparin (including low molecular weight heparins), vitamin K (supplementation or therapeutic dose), vitamin K antagonists (e.g., warfarin, acenocumarol), emtricitabine, tenofovir, adefovir, systemic ketoconazole, adrenocorticotropic hormone, lithium, protease inhibitors, gonadotropin-releasing hormone agonist, aluminum, barbiturate, methotrexate, chemotherapeutic agents, cyclosporine, tacrolimus, or anabolic steroids at any dose within 3 months prior to Screening Visit. Prior/Concurrent Clinical Study Experience

19. Participant is receiving or has received another investigational product within 1 month or 5 half-lives of the other investigational product, whichever is longer, before study intervention administration in this study. Diagnostic Assessments

20. Participant has DXA measurements where:

1. Height, weight, or girth measurements may preclude accurate DXA measurements in the Investigator's opinion.

2. BMD absolute value is consistent with a T-score < -4.0 at the total hip or femoral neck.

21. Participant has severe renal impairment (defined as participant in dialysis or with an eGFR < 30 mL/min per MDRD formula).

22. Participant has inadequate hepatic function (ALT and/or AST = 2 × ULN).

23. Participant presents with clinically significant leukopenia, neutropenia, or anemia as judged by the Investigator. Other Exclusion Criteria

24. Participant has a known intolerance to calcium or vitamin D supplements.

25. Participant has a history of prescription drug abuse or any illicit drug use within 6 months prior to Screening Visit.

26. Participant has a history of alcohol abuse (defined as consuming more than 3 drinks on any day or more than 7 drinks per week) according to medical history within 6 months prior to Screening Visit.

27. Participant is a smoker or has used nicotine and nicotine-containing products within 12 months of Screening Visit.

28. Participant has a known sensitivity to mammalian cell-derived drug products.

29. Participant is immunosuppressed for any reason.

30. Participant has any other conditions including clinically significant medical conditions/disorders/diseases, psychiatric status, or laboratory abnormalities that in the opinion of the Investigator might interfere with the participant's ability to participate in the study, would pose a risk to the participant's safety, or interfere with the study evaluation, procedure, or completion.

Related Conditions & MeSH terms

• Osteoporosis
• Osteoporosis, Postmenopausal

Intervention

Biological:
• Denosumab
Sterile, preservative-free, solution of denosumab packed in 1-mL pre-filled glass syringes for subcutaneous administration.Each syringe contains 60 mg denosumab (60 mg/mL solution) and is intended for single administration once every 6 months.

Locations

Country	Name	City	State
Bulgaria	MHAT Dr. Atanas Dafovski AD	Kardzhali
Bulgaria	Medical Centre Leo Clinic EOOD	Plovdiv
Bulgaria	Diagnostic-consultative center Ascendent EOOD	Sofia
Bulgaria	Medical Center Leo Clinic EOOD	Varna
Czechia	CCR Brno s.r.o.	Brno
Czechia	Synexus Prague	Prague
Japan	Nakamura Hospital	Beppu	Ôita
Japan	Asakawa Orthopedic Clinic	Chikugo	Hukuoka
Japan	Nemoto Geka SeikeiGeka	Fujimi	Saitama
Japan	Kobayakawa Orthopedic Rheumatologic	Fukuroi	Sizuoka
Japan	Gifu Prefectural General Med C.	Gifu	Gihu
Japan	Marunouchi Hospital	Matsumoto-shi	Nagano
Japan	Obase Hospital - Orthopedics	Miyako-gun	Hukuoka
Japan	Shimonoseki City Hospital	Shimonoseki	Yamaguti
Japan	Koenji Orthopedic Surgery	Shinagawa-ku	Tôkyô
Japan	Med Teda Ooimachi Orthopaedic	Shinagawa-ku	Tôkyô
Japan	Himeno Hospital	Yame-gun	Hukuoka
Poland	Centrum Medyczne Pratia Czestochowa	Czestochowa
Poland	Synexus Polska Sp. z o.o.	Czestochowa
Poland	Synexus Polska Sp. z o.o.	Gdansk
Poland	Centrum Medyczne Pratia Gdynia	Gdynia
Poland	Pratia Jelenia Gora	Jelenia Gora
Poland	Centrum Medyczne Pratia Katowice	Katowice
Poland	Synexus Polska Sp. z o.o.	Katowice	Slaskie
Poland	Krakowskie Centrum Medyczne Sp.z o.o.	Krakow
Poland	Pratia MCM Krakow	Krakow
Poland	Centrum Medyczne AMED Oddzial w Lodzi	Lodz
Poland	Synexus Polska Sp. z. o.o.	Lodz
Poland	Synexus Polska Sp. z o.o.	Poznan
Poland	Centrum Medyczne Pratia Poznan	Skorzewo	Wielkopolskie
Poland	Centrum Medyczne Pratia Poznan	Skorzewo	Wielkopolskie
Poland	Centrum Medyczne AMED	Warszawa
Poland	FutureMeds Warszawa Centrum	Warszawa
Poland	Synexus Polska Sp. z o.o.	Warszawa
Poland	FutureMeds Sp. z o.o.	Wroclaw
Poland	Synexus Polska Sp. z o.o.	Wroclaw
United States	Valley Institute of Research	Fort Worth	Texas
United States	Indago Research and Health Center, Inc.	Hialeah	Florida
United States	Clinical Trials Management Services, LLC	Thousand Oaks	California

Sponsors (1)

Lead Sponsor	Collaborator
Luye Pharma Group Ltd.

Countries where clinical trial is conducted

United States,  Bulgaria,  Czechia,  Japan,  Poland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To demonstrate equivalent efficacy between LY06006 and EU-Prolia, in terms of BMD in female participants with postmenopausal osteoporosis;	%CfB in lumbar spine BMD at Month 12	12 months
Primary	EU Marketing Authorization only: To demonstrate similar PD between LY06006 and EU-Prolia, in terms of the bone resorption marker sCTX in female participants with postmenopausal osteoporosis	EU Marketing Authorization only: standardized AUEC0-6m (post first dose) of -%CfB in bone resorption marker sCTX over 6 months	6 months
Secondary	To provide additional comparative efficacy data of LY06006 with EU-Prolia in female participants with postmenopausal osteoporosis	%CfB in lumbar spine BMD at Month 6; %CfB in total hip BMD at Months 6 and 12; %CfB in femoral neck BMD at Months 6 and 12	6-12 months